IPP Bureau
WuXi Biologics launches PatroLab digital twin platform to transform biologics manufacturing
By IPP Bureau - January 16, 2026
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
Alphatec and Theradaptive forge landmark spine partnership as Series B round launches
By IPP Bureau - January 16, 2026
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
Redesigned brain receptor drugs show promise for depression
By IPP Bureau - January 16, 2026
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
AVEO Oncology doses first patient in pioneering AML clinical trial
By IPP Bureau - January 16, 2026
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet
By IPP Bureau - January 16, 2026
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia
By IPP Bureau - January 16, 2026
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
Zydus receives final approval from USFDA for Eltrombopag Tablets
By IPP Bureau - January 16, 2026
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
Sun Pharma launches Unloxcyt for advanced cutaneous squamous cell carcinoma treatment
By IPP Bureau - January 16, 2026
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
Biocon completes Rs. 4,150 crore equity fundraise through QIP
By IPP Bureau - January 15, 2026
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
Max Healthcare teams up with Google to enable direct appointment bookings
By IPP Bureau - January 15, 2026
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors
By IPP Bureau - January 15, 2026
BioNTech maps pivotal oncology milestones for 2026
By IPP Bureau - January 15, 2026
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
CARsgen and Dispatch Bio launch groundbreaking CAR T collaboration in China
By IPP Bureau - January 15, 2026
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
